IeDEA–WHO Research-Policy Collaboration: contributing real-world evidence to HIV progress reporting and guideline development

Journal of Virus Eradication

Olga Tymejczyk¹  Keri N. Althoff²  Sophie Desmonde²  Matthias Egger³  Peter F. Rebeiro⁴  Annette H. Sohn⁵  Nathan Ford⁵  Morna Cornell⁶  Azar Kariminia⁶  Elizabeth Zaniewski⁷  Valériane Leroy⁸  Marcel Yotebieng⁹  Denis Nash^1,10 

[1] Corresponding author: Elizabeth Zaniewski, Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, CH-3012 Bern, Switzerland;Graduate School of Public Health and Health Policy, City University of New York, NY, USA;Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa;Division of Epidemiology, Ohio State University, College of Public Health, Columbus, OH43210USA;Inserm U1027, Université de Toulouse, Toulouse, France;Institute for Implementation Science in Population Health, City University of New York, NY, USA;Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland;Kirby Institute, University of New South Wales, Sydney, NSW, Australia;TREAT Asia/amfAR, Bangkok, Thailand;World Health Organization, Geneva, Switzerland;

关键词: research-policy partnerships;    HIV;    cohort data;    observational data;    World Health Organization;   

DOI  :  

来源: DOAJ

【 摘 要 】

Partnerships between researchers and policymakers can improve uptake and integration of scientific evidence. This article describes the research-policy partnership between the International epidemiology Databases to Evaluate AIDS (IeDEA) (www.iedea.org) and the World Health Organization (WHO), which was established in 2014. IeDEA is an international research consortium, which analyses data on almost 2 million people living with HIV under care in routine settings in 46 countries in Asia-Pacific, the Caribbean, Central and South America, North America and sub-Saharan Africa. Five multiregional analyses were identified to inform the WHO on progress towards the second and third 90s of the 90-90-90 targets in adults and children: (i) trends in CD4 cell counts at the start of antiretroviral therapy (ART); (ii) delays from enrolment in HIV care to ART initiation; (iii) the impact of ART guideline changes; (iv) retention in care, mortality and loss to follow-up; and (v) viral suppression within the first 3 years after initiating ART. Results from these analyses were contributed to the 2015 and 2016 WHO global HIV progress reports, will contribute to the 2018 report, and were published in academic journals. The partnership has been mutually beneficial: discussion of WHO policy agendas led to more policy-framed, relevant and timely IeDEA research, and the collaboration provided the WHO with timely access to the latest data from IeDEA, as it was shared prior to peer-review publication.

【 授权许可】

Unknown